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Abstract. Dengue virus (DENV) is expanding toward previously nonendemic areas. DENV has recently been in-
troduced in Nepal with limited information. We report the clinical features and serotype distribution of DENV in Nepal
during the 2010 outbreaks. A total of 1,215 clinical dengue cases at twomajor hospitals of central andwesternNepalwere
investigated. Demographic, clinical, and laboratory parameters were recorded. Serum specimens were tested for DENV
by IgM/IgG enzyme-linked immunosorbent assays (ELISAs) and reverse transcription polymerase chain reaction (RT-
PCR). We confirmed DENV infection in 403 (33%) patients from 12 districts with an estimated case fatality rate of 1.5%.
DENV infection wasmore common in adults (87%) and urban settings (74%). We detected all four serotypes but DENV-1
and -2 weremainly responsible for major outbreaks (92%). Overall, 60% of all DENV infections were secondary and 17%
were severe dengue; both being more frequent among the DENV-2 infections. Rash, bleeding, abdominal pain, hepa-
tomegaly, elevated liver enzymes, and thrombocytopenia were significantly more common in severe dengue compared
with nonsevere infections. We also confirmed the expansion of dengue to hill urban areas (DENV-1 and -2), including the
capital Kathmandu (altitude, 1,300 m) though > 90% cases were from southern plains. Differential clinical and laboratory
features probably help in clinical decisions. Multiple serotypes circulation and elevated secondary infections pose po-
tential risk of severe outbreaks and deaths in the future. Therefore, a country with recent dengue introduction, like Nepal,
urgently requires a systematic surveillance and appropriate control measures in place to respond to any disastrous
outbreaks.
INTRODUCTION
Global distribution of dengue virus (DENV) is constantly
expanding and poses a significant health problem with
390million dengue infections/year frommore than 100 countries,
96 million of which are clinical.1–3 These figures may still un-
derestimate the actual dengue burden given the dramatic ur-
banization and inadequate dengue surveillance in tropical
developing countries.4 The World Health Organization (WHO)
South East Asia Region (SEAR) holds 50% of the global
dengue burden and its member states are experiencing an
upsurge in reported cases of dengue.2,5
DENV infections range from asymptomatic and un-
differentiated fever to severe dengue manifestations. Occa-
sionally, unusual complications such as cardiomyopathy,
acute liver/renal failure, and encephalopathy/encephalitis have
also been reported during dengue infections, even in the ab-
sence of severe plasma leakage or shock.2,6 Several studies
onclinical featuresofDENV infections inbothhospital patients
and community cohorts indicate that clinical features are not
uniform across the countries/continents, raising questions on
their universal application in clinical settings.7–15 Most reports
cover relatively well-resourced countries. There are few re-
ports describing clinical features of DENV infections in
resource-poor areas.
On the basis of the recent epidemiological reports, dengue
has rapidly expanded to newareas (previously naı̈ve) including
Nepal.2,3,5,16–18 This is a global health concern and in-
vestigation in such areas provides crucial information for un-
derstanding the changing epidemiology. The first dengue
outbreak in Nepal was documented in 2006, followed by a
handful of sporadic reports.16,19–21 Due to the lack of ade-
quate laboratory infrastructures, limited information is avail-
able on the prevailing serotypes from Nepal.16 Dengue
remainedmostly unrecognized during 2007–200918 until large
outbreaks occurred in central andwestern Nepal during 2010,
at least 4 years after the first introduction of the virus in the
country. The lack of data on DENV serotype, clinical mani-
festation, travel history of most patients and disease outcome
during the 2006 outbreak has certainly left a significant
knowledge gap. In this report, we describe the serological and
molecular investigation coupledwith demographic features of
major outbreaks in Nepal to aid in understanding of regional
epidemiology. Furthermore, we also sought to provide basic
clinical features of DENV infections (including serotype based




This observational study was conducted in two major
tertiary care hospitals (Bharatpur Hospital, Chitwan in
central and Lumbini Zonal Hospital, Rupandehi in western
Nepal) during the large outbreak episodes to measure
the dengue burden and identify the prevalent DENV sero-
types along with their clinical features. Apart from southern
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districts, some patients from the country’s capital (Kathmandu
valley) were also included in the study. A total of 1,215 febrile
subjects (all age/sex) with clinical presentation similar to den-
gue6 were enrolled. A predefined set of clinical and de-
mographic parameters were recorded on their first hospital
visit and acute blood specimens were collected by veinpunc-
ture. Selected laboratory parameters (biochemical and he-
matological) were recorded. Similarly, after 2 weeks, a second
(convalescent) blood sample was also obtained from the
subjects at hospital (in-patients) or during their follow-up visits.
Days postonset of illness (DOI) was considered as the time
interval between onset of fever (considered day 1) and the day
of hospital visit. Outcome of the illness was also recorded.
Definition of dengue and nondengue cases. Dengue
classification (dengue fever [DF]; dengue hemorrhagic fever
[DHF]; dengueshock syndrome [DSS])wasbasedon theWHO
guidelines of 1997.6 Patients’ specimens positive by dengue
enzyme-linked immunosorbent assay (ELISA) and/or reverse
transcription polymerase chain reaction (RT-PCR) were con-
sidered as “dengue” cases, whereas those negative by both
ELISA and RT-PCR were concluded as “nondengue.” DHF
and DSS were considered “severe dengue.” Information from
these selected confirmed cases was used to compare clinical
characteristics and laboratory parameters in dengue and
nondengue populations of Nepal. For liver enzymes (serum
aspartate aminotransferase [AST]; serum alanine amino-
transferase [ALT]), a value > 50 IU/L was considered as “ele-
vated.” Conditions with the platelet counts < 100,000/mm3
and white blood cell counts < 4,000/mm3 were considered as
thrombocytopenia and leucopenia, respectively.
Laboratory methods. Each serum specimen was divided
into three aliquots for serology, molecular detection and vi-
rological assays, and stored at −80C or liquid nitrogen as
appropriate.
DENV specific IgG and IgM ELISAs. Specimens were
assayed by DENV specific IgG and IgM ELISA (Standard Di-
agnostics, Inc., Yongin-si, Republic of Korea). Since the out-
break areas were previously reported as Japanese encephalitis
(JE) endemic,22 specimens were also tested for JE using a ref-
erence standard IgM capture ELISA.23 There was no Zika virus
(ZV) screening of these samples as no ZV has been reported in
the country. In addition, malariamicroscopywas also performed
in these febrile cases. Immune responses (primary or second-
ary) were determined by previously established serological
techniques (IgG/IgM ELISA) in selected patients’ specimens
(both acute and convalescent sera) available in adequate
quantity (N=279).23Additionally, asa routine, IgGand IgMrapid
diagnostic test (RDT) (Standard Diagnostics, Inc.) was also
used by each health facility.
Viral RNA detection and serotyping by RT-PCR. Serum
samples from 282 cases were randomly selected for molec-
ular analyses, approximately maintaining the original propor-
tion of serological dengue positive and negative population
(Figure 1). DENV detection and serotyping was performed as
described previously with some modifications.24 Briefly, viral
RNA was extracted from 140 μL of patient’s serum using the
commercial kit (QIAmp® Viral RNA Mini Kit, QIAGEN, Ger-
many) and amplified by first round RT-PCR using Avian
Myeloblastosis virus Reverse Transcriptase (Promega, Mad-
ison, WI) in 50 μL final volume of reaction mixture containing
consensus primers (D1 and D2; Supplemental Table 1). RT-
PCR was done as follows: 42C for 1 hour followed by
35 cycles of 94C for 30 seconds, 55C for 1 minute and 72C
for 2 minutes each. In the nested PCR step (second round),
5 μL of 1:50 diluted RT-PCR product was further amplified in a
reaction mixture (50 μL final volume) containing D1 and se-
rotype specific (TS1–4) primers (Supplemental Table 1) for 25
cycles under the same thermal conditions. Mixtures of known
DENV-1 to -4 isolates and DENV-1 to -4 RNA were re-
spectively used as positive controls for RNA extraction and
PCR assays.
Data analysis.Mortality rate was estimated as case fatality
rate (CFR) based on the deaths due to confirmed DENV. Dif-
ferences in the demographic, clinical, and laboratory features
between dengue and nondengue, and dengue and severe
dengue populations, and outbreak sites were determined
by Pearson’s χ2 test for categorical variables. Data distri-
bution (normality) was determined for continuous variables
by Kolmogorov–Smirnov/Shapiro–Wilk tests as appropriate.
To draw the statistical difference of continuous variables in
two groups and more than two groups, Mann–Whitney U test
and Kruskal–Wallis test were used, respectively. Measures of
central tendency for continuous variables were expressed as
median [25–75% interquartile range (IQR)]. Statistical signifi-
cance was set at P < 0.05 at 2-sided test statistics. Data were
organized on MS Excel and analyzed by using SPSS Version
17. MapWindow GIS v4.8.6 software (Geospatial Software
Laboratory, Idaho State University, Pocatello, ID) was used to
locate and present the dengue cases in the country map.
Ethical approval and informed consent. Ethical approval
was obtained from the Nepal Health Research Council
(NHRC), Kathmandu, Nepal and the WHO-Ethics Review
Committee, Geneva, Switzerland. Written informed consent
was obtained from the subjects enrolled in the study (or their
legal guardians) as appropriate.
RESULTS
Description of outbreak. Beginning in mid-August 2010, a
sudden upsurge in febrile cases was reported in some
southern tropical districts of central and western Nepal where
FIGURE 1. Summary of the case processing strategy and laboratory
assays performed. ELISA = enzyme linked immune-sorbent assay;
RT-PCR = reverse transcription polymerase chain reaction; JE =
Japanese encephalitis. Among the total 3,845 febrile cases reported,
1,215 were clinical dengue cases.
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vector-borne diseases are endemic. Bharatpur Hospital,
Bharatpur, Chitwan in central Nepal and Lumbini Zonal Hos-
pital, Butwal, Rupandehi in western Nepal reported large
number of febrile cases (N = 3,845) until December. Both of
these public hospitals have wide catchment areas and very
high patient flow as the country’s major highways pass
through these two cities. These southern plains are either
abundant in mosquito vectors (Aedes aegypti and Aedes
albopictus) or earlier reported the presence of DENV.16 A no-
table proportion of the febrile patients (N= 1,215; 31.6%)were
clinical dengue cases (Figure 1).
Demographic findings. Out of 1,215 clinically diagnosed
dengue cases reported from 24 districts during the outbreaks,
403 (33%) patients from 12 districts were confirmed to have
dengue infection by ELISA and RT-PCR (Table 1, Figure 2).
Seven JE and three malaria positive subjects were excluded
from further analysis (Figure 1). The median age (IQR) of
dengue patients was 29.5 (21.3–40.0) years, and dengue was
found to be more common in males (P < 0.001) with the ratio
(male:female) of 1.78, and among the adults (86.8%) com-
pared with children up to 15 years (child:adult = 1:6.6)
(P = 0.001) (Tables 1 and 2). Majority of the dengue patients
(60%) had secondary infections (Table 2) and severe dengue
was significantlymore common in secondary infections (84%)
compared with primary infections (P = 0.002).
Features of dengue outbreak in the central and
western Nepal.We further analyzed the regional variation in
the outbreak pattern. Most characteristic features of the
outbreak were similar in both regions (Table 2). Of the 403
dengue positive cases, the majority (293, 72.7%) were from
six central districts and the rest (110, 27.3%) fromsix districts
ofwesternNepal. The proportion of urban denguewashigher
in the western region compared with the central (P = 0.041).
Overall, 18.1% (73/403) of cases (48, 11.9% in central; 25,
6.2% in western) had severe dengue (DHF/DSS); however,
the proportion of the severe manifestations was relatively
higher (48/293, 22.7%) in western Nepal compared with
central (25/110, 16.4%). Only 12% of the dengue patients
were managed as out-patients while the majority (88%) re-
quired admission. The proportions of child cases, severe
dengue, gender and inpatients were not significantly differ-
ent in two regions. However, the prevalence of primary ver-
sus secondary infections significantly differed at the two
outbreak sites (P < 0.001) with the proportion of secondary
infections being 52.0% in central and 79.7% in western
Nepal (Table 2).
Seasonality of dengue. The dengue outbreak started on
the third week of August and first week of September re-
spectively in the central (Chitwan) and western (Butwal) Nepal
(Figure 3). Tenmore surrounding districts were affected within
2 months. The epidemiological curve peaked during October
and November (with 34.7% and 45.4% of all cases, re-
spectively) reflecting the dengue seasonality in Nepal
(P < 0.001). The number of cases dwindled significantly by the
end of December. Overall, the increased transmission of dengue
coincided with the postmonsoon period in the country.
Clinical and laboratory profile of dengue and
nondengue patients. Dengue patients were significantly
older than nondengue patients (median [IQR] age in years =
29.5 [21.3–40.0] versus 26.0 [17.0–40.0]; P = 0.004) (Table 3).
However, the DOI was not significantly different between
dengue and nondengue febrile illnesses (P = 0.503). In-
terestingly, DOI was significantly shorter in children up to
15 years comparedwith adults (median [IQR] DOI in days = 3.0
[2.0–4.0] versus 5.0 [3.0–7.0]; P = 0.008). Detailed clinical and
laboratory profiles among dengue and nondengue patient are
depicted in Table 3. Most common clinical presentations in
dengue patient were fever, headache, nausea, retro-orbital
pain, rash, vomiting, and myalgia. Rash (P < 0.001), bleeding
(P < 0.001), vomiting (P = 0.029), retro-orbital pain (P = 0.001),
hepatomegaly (P = 0.042), elevated AST/ALT (P < 0.001),
thrombocytopenia (P<0.001) and leucopenia (P= 0.003)were
significantly common among dengue patient compared with
nondengue, whereas chills (P = 0.001) was more frequent
among nondengue patient. Other clinical features were not
significantly different in dengue and nondengue populations.
Among the dengue confirmed cases, rash (P = 0.011),
bleeding (P < 0.001), abdominal pain (P = 0.005), hepato-
megaly (P < 0.001), elevated liver enzymes (P < 0.001), and
thrombocytopenia (P < 0.001) were significantly common in se-
vere dengue cases (DHF/DSS) compared with nonsevere den-
gue cases (DF). There was no difference in the frequency of
severe dengue infection between children andadults (P=0.187).
DENV distribution—multiple serotypes co-circulation
and expansion toward northern highlands. We selected
282 patients’ sera (both ELISA-positive and ELISA-negative)
for RT-PCR analyses (Figure 1). Overall, DENV-1 (64.4%) and
DENV-2 (27.8%) were the most common serotypes found,
TABLE 1
Demographic distribution of dengue patients, Nepal
Variable Total cases (%) Confirmed DENV cases (%) Percentage of dengue positive cases (%)
Sex (P < 0.001)*
Male 645 (53.1) 258 (64.1) 258/645 (40.0)
Female 570 (46.9) 145 (35.9) 145/570 (25.4)
Total 1,215 (100.0) 403 (100.0) 403/1,215 (33.2)
Age group (P = 0.001)*
£ 5 32 (2.6) 5 (1.3) 5/32 (15.6)
6–15 199 (16.4) 48 (11.9) 48/199 (24.2)
Subtotal, children £ 15 231 (19.0) 53 (13.2) 53/231 (22.9)
16–30 491 (40.4) 179 (44.4) 179/491 (36.5)
31–45 296 (24.4) 113 (28.0) 113/296 (38.2)
46–60 121 (10.0) 38 (9.4) 38/121 (31.4)
> 60 76 (6.2) 20 (5.0) 20/76 (26.3)
Subtotal, adults > 15 984 (81.0) 350 (86.8) 350/984 (35.6)
Total 1,215 (100.0) 403 (100.0) 403/1,215 (33.2)
DENV = dengue virus.
*P value was calculated using χ2 test.
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though two cases of DENV-3 and five of DENV-4 were also
confirmed (Table 4). One patient had a mixed infection with
DENV-1 and -2. In the central Nepal, DENV-1 (75.0%) was
foundmore common,whereasDENV-2 (68.2%)was themajor
serotype in the west (P = 0.001). DOI varied depending on the
infecting serotypes with the shortest being DENV-1 infection
(medianDOI [IQR]=3.0 [2.0–4.0]) (P=0.01). Both the secondary
immune response (P = 0.014) and severe dengue (P = 0.01)
were significantly more frequent among DENV-2 infected
subjects (Table 4). We found that dengue (DENV-1 and -2)
had expanded to peri-urban and rural settings in the hill dis-
tricts (Tanahun, Gorkha, Makawanpur, Kathmandu, and
Lalitpur) reporting 18 confirmed cases with no travel history to
endemic area for past 90 days (Figure 2).
Dengue-related fatalities. A total of 26 adult patients died
during hospitalization or during the course of treatment. We
detected dengue (either by RT-PCR or by combination of
ELISA and RT-PCR) in six (four DHF, two DSS) of the 12 fatal
cases from which we had available specimens (Table 5). This
was the first outbreak with confirmed deaths due to any DENV
serotypes (DENV-1 and -2) from Nepal, leaving an estimated
overall CFR of 1.5% (8% in severe dengue). There were no
dengue-related fatalities among children. The major compli-
cations were severe bleeding, acute organ failure, prolonged
shock, and neurological manifestation. In fatal cases, ranges
of time between the onset and hospital visit, and duration of
hospitalization were 4–7 days and 1–7 days, respectively.
Initial clinical diagnosis was poor among fatal dengue cases
(50% correct diagnosis).
DISCUSSION
Here, we report the serotype distribution, clinical, labo-
ratory, and demographic profiles of DENV infections in
Nepal during 2010. This study was limited to subjects at-
tending government hospitals. Therefore, clinical and
FIGURE 2. Distribution of dengue cases in Nepal. Clinical dengue cases (N = 1,215) were reported from 24 districts (shaded areas), and dengue
virus infection was confirmed (N = 403) in 12 districts (dotted areas).
TABLE 2
Characteristic features of dengue outbreaks in central and western Nepal
Variables Subgroup Central (N = 293) Western (N = 110) Total (N = 403) P value
Outbreak period – August–December September–December August–December –
Number of endemic districts – 6 6 12 –
Serotypes – All 4 DENV-1, -2 All 4 –
Age in years, median (IQR) – 30.0 (22.0–44.0) 28.0 (21–37.8) 29.5 (21.3–40.0) 0.407
Age group (years) £ 15 36 (12.3) 17 (15.5) 53 (13.2) 0.402
> 15 257 (87.7) 93 (84.5) 350 (86.8)
Sex Male 192 (65.5) 66 (60.0) 258 (64.0) 0.303
Residence Urban 210 (71.7) 90 (81.8) 300 (74.4) 0.041
Rural 83 (28.3) 20 (18.2) 103 (25.6)
Prior visit to clinics Yes 137 (46.8) 47 (42.7) 184 (45.7) 0.469
No 156 (53.2) 63 (57.3) 219 (54.3)
Clinical spectrum* DF 245 (83.6) 85 (77.3) 330 (81.9) 0.301
DHF 45 (15.4) 24 (21.8) 69 (17.1)
DSS 3 (1.0) 1 (0.9) 4 (1.0)
Immune response† Primary 96 (48.0) 16 (20.3) 112 (40.1) < 0.001
Secondary 104 (52.0) 63 (79.7) 167 (59.9)
Patient management Outpatient 38 (12.9) 11 (10.0) 49 (12.2) 0.416
Inpatient‡ 255 (87.1) 99 (90.0) 354 (87.8)
DOI = days postonset of illness; DF = dengue fever; DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome; ICU = intensive care unit; IQR = interquartile range. Figures in the
parenthesis indicate percentages unless otherwise indicated. P value was calculated using Mann-Whitney U test for age and χ2 test for other categorical variables.
* DHF and DSS were considered severe dengue.
†Data based on dengue patients (N = 279) with paired sera available for immune response determination.
‡ Inpatient data also includes 11 (2.7%) ICU patients (nine from central and two from western Nepal).
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laboratory profiles and actual picture of serotypes
distribution/features are only attributable to public hospi-
tals in Nepal.
Although we were unable to serotype all DENV positive
samples, we could establish that the outbreaks were mostly
caused by DENV-1 (most common in the central region) and
DENV-2 (western region), a departure from the 2006 outbreak,
when DENV-3 was most dominant.16 Also unlike previous
outbreaks in Nepal, the 2010 outbreakswere characterized by
the autochthonous transmission of all four DENV serotypes
(no travel history among the patients) and all serotypes cir-
culation even in a single location.
The Nepal DENV likely originated in India, given the two
countries proximity and the geological, climatic, and so-
cioeconomic similarities. This may also explain the simi-
larities in temporal variation and seasonality between the
Nepal 2010 outbreaks and contemporaneous Indian
outbreaks.25–29 Three-fourths of the dengue cases in this
study occurred in urban settings, reflecting the urban nature
of the virus.2 Factors related to mosquito invasion, in-
creased travel among the populace, urbanization, and
globalization,30 and climate change31 have been postulated
as the drivers of the expanding epidemic and could explain
the introduction of DENV into Nepal and into its rural
FIGURE 3. Epidemiological curve of dengue outbreaks, Nepal. Y-axis indicates the number of cases. Y-axis indicates the number of cases.
Western indicates clinical dengue cases from Lumbini Zonal Hospital, Butwal, Rupandehi, and central indicates cases from Bharatpur Hospital,
Bharatpur, Chitwan. This figure appears in color at www.ajtmh.org.
TABLE 3
Demographic, clinical and laboratory profile of dengue and nondengue patients, Nepal
Variable Dengue (N = 128) Nondengue (N = 154) Total (N = 282) P value
Demographic
Age in years, median (IQR) 29.5 (21.3–40.0) 26.0 (17.0–40.0) 28.0 (19.0–40.0) 0.004
Residence, urban 93 (72.7) 65 (42.2) 158 (56.0) < 0.001
Prior visit to clinics/pharmacy 58 (45.3) 67 (43.5) 125 (44.3) 0.761
Clinical
DOI, median (IQR) 4.5 (3.0–7.0) 4.0 (2.0–7.0) 4.0 (2.8–7.0) 0.503
Fever 128 (100.0) 154 (100.0) 282 (100.0) –
Headache 118 (92.2) 134 (87.0) 252 (89.4) 0.161
Nausea 91 (71.1) 97 (63.0) 188 (66.7) 0.150
Vomiting 46 (35.9) 37 (24.0) 83 (29.4) 0.029
Rash 48 (37.5) 21 (13.6) 69 (24.5) < 0.001
Myalgia 44 (34.4) 52 (33.8) 96 (34.0) 0.914
Bleeding 18 (14.1) 4 (2.6) 22 (7.8) < 0.001
Retro-orbital pain 56 (43.8) 39 (25.3) 95 (33.7) 0.001
Diarrhea 29 (22.7) 25 (16.2) 54 (19.1) 0.172
Sore throat 9 (7.0) 22 (14.3) 31 (11.0) 0.053
Chills 12 (9.4) 37 (24.0) 49 (17.4) 0.001
Abdominal pain 36 (28.1) 49 (31.8) 85 (30.1) 0.501
Arthralgia 19 (14.8) 17 (11.0) 36 (12.8) 0.340
Hepatomegaly 43 (33.6) 35 (22.7) 78 (27.7) 0.042
Splenomegaly 17 (13.3) 11 (7.1) 28 (9.9) 0.086
Laboratory
Elevated AST (> 50 IU/L) 81 (63.3) 44 (28.6) 125 (44.3) < 0.001
Elevated ALT (> 50 IU/L) 57 (44.5) 28 (18.2) 85 (30.1) < 0.001
Thrombocytopenia 75 (58.6) 35 (22.7) 110 (39.0) < 0.001
Leucopenia 55 (43.0) 40 (26.0) 95 (33.7) 0.003
AST=serumaspartate aminotransferase; ALT= serumalanine aminotransferase;DOI = dayspostonset of illness; IQR= interquartile range; IU/L= international unit/liter. Figures in theparenthesis
indicate percentages unless otherwise indicated. P value was calculated using Mann–Whitney U test for age and DOI, and χ2 test for all categorical variables.
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areas.27,32 Underscoring the expanding epidemiology of
DENV is the presence of the virus in the northern hills of
Nepal, including the capital city, Kathmandu (1,300 m alti-
tude). At this altitude, DENV is infrequent as A. aegypti is
relatively uncommon.2
Accurate detection of DENV required the use of both ELISA
and RT-PCR (Supplemental Figure 1) rather than reliance in a
single assay as results vary significantly depending on the
DOI.2 Dengue detection rate by single serology (ELISA) and
PCR was 29.8% and 31.9%, respectively. When their com-
bination was used, the detection rate improved to 45.4%. The
government of Nepal routinely provides free RDTs during
outbreaks, and these are used to test single acute serum
samples for diagnosis regardless of when after illness onset
was the sample collected. This, combined to the RDT’s own
limitations,33,34 leads to incorrect estimation of the burden of
the disease. Unfortunately, themeans to perform RT-PCR are
largely lacking in Nepal and paired sera are not routinely col-
lected in peripheral health care units. The need to improve
dengue diagnosis can be addressed (to some extent) by in-
corporating additional early (antigen) detection assays such
as nonstructural protein-1 (NS-1) detection35 alongwith serology
to improve diagnosis, and facilitate proper patient management.
Early hospital visit (shorter illness duration) by urban (ver-
sus rural) residents signals their increased awareness and
access to hospitals compared with their rural counterparts
who substantially delay hospital attendance. Most dengue
patients (88%) were hospitalized although only 18% of them
were severe. Lack of laboratory facilities in resource-limited
areas15 and inefficient classification and management ex-
perience may have contributed to unnecessarily higher
hospitalization rates in Nepal. As expected, severe dengue
was more common in secondary infections compared with
primary.10,11
Characteristics of the illness varied slightly depending on
the infecting serotype. Secondary infections were more
commonly found in DENV-2 infections, which may have led to
higher viremia inpatients andmore severemanifestationof the
disease.11 Likewise, primary infections were more common
among DENV-1 patients. In addition to clinical features pre-
viously described in DENV infections,13,15 we observed sig-
nificantly higher frequency of vomiting, retro-orbital pain,
hepatomegaly and elevated AST/ALT in the dengue pop-
ulation (versus nondengue), which are not commonly report-
ed.12 Some of these clinical manifestations (rash, bleeding,
abdominal pain, hepatomegaly, thrombocytopenia, and ele-
vated AST/ALT) were more common in severe DENV infecti-
ons (versusDF). Thrombocytopenia, leucopenia, and elevated
liver enzymes were found significantly associated with both
dengue (versus nondengue) and severe dengue (versus DF).
Similar patterns are also reported elsewhere.36–38 These dis-
criminatory features may be useful in patient management to
TABLE 4
Characteristic features associated with different DENV serotypes, Nepal
DENV-1 (N = 58) DENV-2 (N = 25) DENV-3 (N = 2) DENV-4 (N = 5) P value
Age in years, median (IQR) – 29.0 (17.8–40.0) 28.0 (15.5–36.0) ND 25.0 (20.0–37.5) 0.696
Age group (years) £ 15 9 (15.5) 6, 24.0 0 0 0.489
> 15 49 (84.5) 19 (76.0) 2 (100.0) 5 (100.0)
DOI median (IQR)* – 3.0 (2.0–4.0) 4.0 (3.0–5.0) ND 6.0 (4.0–6.0) 0.01
Sex Male 41 (70.7) 15 (60.0) 2 (100.0) 3 (60.0) 0.571
Outbreak site Western 7 (12.1) 15 (60.0) 0 0 < 0.001
Central 51 (87.9) 10 (40.0) 2 (100.0) 5 (100.0)
Immune response† Primary 38 (65.5) 7 (28.0) 2 (100.0) 1 (20.0) 0.014
Secondary 20 (34.5) 18 (72.0) 0 4 (80.0)
Disease spectrum DF 52 (89.7) 16 (64.0) 2 (100.0) 5 (100.0) 0.01
DHF/DSS 6 (10.3) 9 (36.0) 0 0
DENV=dengue virus; DF= dengue fever; DHF=dengue hemorrhagic fever; DOI = dayspostonset of illness; DSS=dengue shock syndrome; IQR= interquartile range; ND= not done.P valuewas
calculated for age and DOI by Kruskal–Wallis test in three groups (DENV-1, -2, and -4).
* DOI difference between two groups was estimated by Mann–Whitney U test for DENV-1 vs. -2 (P = 0.023), DENV-1 vs. -4 (P = 0.007) and DENV-2 vs. -4 (P = 0.112). For categorical variables,
difference was calculated using χ2 test. DENV-3 was not included in the statistical analysis due to small sample size (N = 2). Figures in the parenthesis indicate percentages unless otherwise
indicated.
†Secondary infection was more common with DENV-2 compared with DENV-1 (P = 0.002).
TABLE 5
Details of patient fatalities during the 2010 dengue outbreaks, Nepal
Patient No. Age/Sex DOI (day) Hospitalized time (day) Initial clinical diagnosis* Dengue RDT (routine)* Dengue ELISA JE IgM ELISA Dengue RT-PCR
1 56/F 7 5 Dengue Positive Negative Negative Negative
2 41/M 4 4 Malaria Negative Negative Negative DENV-1
3 27/M 8 2 Dengue Negative Negative Negative Negative
4 35/F 4 5 Leptospirosis Negative Positive Negative DENV-1
5 29/M 7 3 Dengue Positive Positive Negative DENV-1
6 14/M 2 10 UFI Negative Negative Negative Negative
7 45/M 5 6 Dengue Positive Negative Negative Negative
8 18/M 7 5 Dengue Positive Positive Negative DENV-2
9 32/F 5 2 Dengue Positive Negative Negative Negative
10 33/M 6 7 JE Negative Positive Negative DENV-2
11 21/F 4 1 Dengue Negative Negative Negative DENV-2
12 10/F 8 7 UFI Negative Negative Negative Negative
DOI = days postonset of illness; ELISA = enzyme linked immune-sorbent assay; F = female; JE = Japanese encephalitis; M = male; RDT = rapid diagnostic test; RT-PCR = reverse transcription
polymerase chain reaction; UFI = undifferentiated febrile illness.
* RDT (supplied by the government) was performed by each health facility. Data on RDT and initial diagnosis was obtained from medical records.
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allow careful monitoring for severe dengue development.
Nonetheless, clinical decisions should not solely depend on
these features alone. Clinical features have great value when
organized into a prognostic algorithm for early prediction of
dengue severity.39
In some countries, dengue is the leading cause of child
hospitalization and death.2,28 Although most studies focus on
pediatric dengue,2,25,28,32 we found more frequent DENV in-
fections in Nepalese adults, though without differences in
severity. When studies address dengue in adults,9,10,13,26,40 it
is often in response to the virus recent introduction in an area.
High frequency of adult dengue diagnosis may be attributable
to lack of immunity in adults or relatively less symptomatic
dengue in children.41 We noticed more DENV infections in
males as reported before,26,27,36 perhaps due to higher oc-
cupational exposure to the vector amongmen, clothing habits
and increased access to healthcare for diagnosis.16
Despite reports of sporadic dengue cases, dengue-
associated fatalities had not been reported before 2010 in
Nepal.18 The estimated 2010 dengue CFR was 1.5%, al-
though only 12 of all these fatal cases were tested by RDT and
of these, only sixwereconfirmed inour studybydengueELISA
and/or RT-PCR. This CFR is slightly higher than the average
fatality rate in the SEAR (∼1%).2 Similar to other reports.8,9
massive gastrointestinal bleeding and prolonged shock were
the main causes of dengue-associated deaths in Nepal. In-
correct diagnosis based on clinical observations or RDTs led
to treatment deviations in some fatal cases (a patient with
neurological manifestations was erroneously diagnosed as
JE, and nondengue case considered dengue) (Table 5). Neu-
rological signs in dengue42 and treatment deviation due to
misdiagnosis in fatal cases have also been reported pre-
viously.8 Further longitudinal and prospective studies are
warranted for better understandingof dengueepidemic trends
in Nepal.
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